Search

Additional file 1: Figure S1. (A) Powder sample of prepared dMn3O4 (B) Schematic representation and (C) EDS analysis of dMn3O4. Figure S2. XPS analysis individual peaks in dMn3O4. Figure S3. NMR analysis (A) PTC and (B) PC. Figure S4. Low magnification FE-TEM images of (A) PTC (B) PC-M, PC-M + H2O2, PTC-M and PTC-M + H2O2. Figure S5. EDS elemental mapping of PTC-M. Figure S6. (A) Lyophilized sample of PTC-M (B) TGA analysis. Figure S7. (A) Hydrodynamic diameter and (B) zeta potential of PTC-M and PC-M before and after exposure to H2O2. Figure S8. (A) Hydrodynamic size distribution and (B) zeta potential of empty nanomicelles (PTC and PC) before and after treatment with H2O2. Figure S9. Stability of PTC-M in 10% FBS. Figure S10. Catalase like activity of PTC-M at different concentrations. Figure S11. (A) Disproportionation of H2O2 by PTC-M resulting in bubble formation (B) Dissolved oxygen production by dMn3O4 and PTC-M. Data is shown as mean ± SEM (n = 3 replicates). Statistics were performed by a one-way ANOVA (*P < 0.05, **P < 0.01, *** P < 0.001, and **** P < 0.0001). Figure S12. In vitro cell viability of the empty nanomicelles (PTC, PC) as well as dMn3O4 loaded nanomicelles (PTC-M, PC-M). Figure S13. Cellular uptake and intracellular IR780 release. High magnification images (Scalebar=75µm). Figure S14. (A) Ex-vivo images of organs at different time points post injection form I/R model mice administered with PC-IR780 and IR780 (B) NIRF signal intensity quantification from isolated kidneys of PTC-IR780, PC-IR780 and IR780 administered mice in I/R model at different time points. Figure S15. Ex-vivo images of major organs at different time points post injection form normal C57 mice administered with PTC-IR780. Figure S16. ICP-MS analysis of major organs, feces and urine collected from AKI mice administered with PTC-M at 72 h and 168h. Figure S17. H & E staining of all major organs (liver, lung, spleen, heart, and intestine) collected from the control and PTC-M treated AKI mice (at 72 h), scale bar = 200 μm. Table S1. List of primary and secondary antibodies for immunoblotting. Table S2. List of primer sequences for real-time qPCR. Table S3. List of primary and secondary antibodies for immunohistochemistry.

Development of simple and fast acting pharmaceutics that can be administered orally or as injectable forms has been a major concern for the pharmaceutical industries, but during last decades, this trend has changed to the development of effective formulations for efficient drug delivery. Non-degradation of drug carriers and reduced therapeutic potency of the drug before it reaches specific targets in the body are major challenges in contemporary drug delivery systems. Rather than discovering new drug molecules, which is expensive and time consuming, researchers are involved in improving the safety efficacy ratio of the existing drugs by designing efficient formulation that can target these drugs to specific sites and can control the drug delivery rate and period. A myriad of drug delivery systems, based on organic as well as inorganic materials, have been used to achieve this goal. Among these, nanogels, which are hydrogels in nanoscale dimensions, take over an important role in tackling the clinical and pharmacological limitations of current systems. The development of injectable nanogel systems can prevail over difficulties in the ease of application of hydrogel-based drug delivery system in clinic. In this chapter, we discuss nanogels, particularly on injectable nanogels, different polymers and various synthesis methods involved in their preparation, mode of action and their fate under physiological conditions. The chapter also discusses different applications of injectable nanogels with special reference to drug delivery and how these innovative class of system can reinstate our existing drug delivery systems.